Cardio Metabolic RiskPhase 3NCT07609043
Impact of Prasterone on Cardiometabolic Indicators in Perimenopausal Women.
A Phase 3 study testing Prasterone 50 milligram in people with Cardio Metabolic Risk, run by Universidad de Guanajuato at 1 site in Mexico.
Trial summary
Perimenopause is the natural transition period towards menopause, in which the ovarian reserve begins to decrease, and the woman loses her fertility. It usually starts around the age of 40 and has a variable duration. Read more about this study
- Who is it for?
- Ages 42 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cardio Metabolic Risk
- What is being tested?
- Prasterone 50 milligram
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteMexico
- Study dates
- 10 Jan 2020to 10 Jan 2021
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 42 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- with no history of breast cancer, HRT, morbid obesity, cardiovascular disease, or DM.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Perimenopause is the natural transition period towards menopause, in which the ovarian reserve begins to decrease, and the woman loses her fertility. It usually starts around the age of 40 and has a variable duration. It has been identified that the decrease in estrogen levels leads to the development of metabolic and cardiovascular complications, such as metabolic syndrome. Dehydroepiandrosterone (DHEA) is a hormone that converts to testosterone and estrogen and is mainly associated with age-related changes in cardiovascular tissues and metabolism, among others. This hormone declines with age, contributing to the development of age-related disorders, such as cardiovascular disease. In theory, DHEA has beneficial effects in regulating glucose and lipid metabolism and in ameliorating obesity. It is hypothesized that DHEAS and cardiovascular disease may share causal pathways, for example, nitric oxide synthesis and endothelial cell damage. In addition, it has been observed that the administration of DHEA significantly reduces the level of triglycerides and improves insulin sensitivity. There are few studies focused on the perimenopause stage and none of them focused on the prevention of cardiometabolic risk. Therefore, evaluating the impact of prasterone on cardiometabolic indicators in premenopausal women is essential.
Read the detailed description
Perimenopause is the natural transition period towards menopause, in which the ovarian reserve begins to decrease, and the woman loses her fertility. It usually starts around the age of 40 and has a variable duration. It has been identified that the decrease in estrogen levels leads to the development of metabolic and cardiovascular complications, such as metabolic syndrome. Dehydroepiandrosterone (DHEA) is a hormone that converts to testosterone and estrogen and is primarily associated with age-related changes in cardiovascular tissues, female fertility, and metabolism, among others. This hormone gradually declines with age, contributing to the development of age-related disorders, such as cardiovascular disease. In theory, DHEA has beneficial effects in regulating glucose and lipid metabolism and in ameliorating obesity. Previous studies have shown that DHEA is inversely associated with cholesterol levels, obesity, and diabetes, playing an important preventive role in cardiovascular disease. It is hypothesized that DHEAS and cardiovascular disease may share causal pathways, for example, nitric oxide synthesis and endothelial cell damage. Some studies in premenopausal women found inverse correlations between serum DHEA concentrations and body weight. Besides. It has been observed that the administration of DHEA significantly reduces the level of triglycerides and improves insulin sensitivity. A meta-analysis showed that DHEAS was lower in patients with coronary disease, therefore, it is suggested that low levels of DHEAS may be a risk factor for coronary disease, affecting quality of life, and increasing the risks that predispose to metabolic diseases. Most of the studies where DHEA is administered are focused on the menopause stage, there being few studies focused on the perimenopause stage and none of them on the prevention of Cardiometabolic risk. For this reason, it is important to carry out studies to find out the effects that prasterone has on cardiometabolic indicators and that can contribute to the understanding of these processes before menopause appears. This study was conducted in 25 women older than 42 years in the perimenopausal stage, with no history of breast cancer, hormonal replacement therapy , morbid obesity, cardiovascular disease, or diabetes mellitus. They were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (baseline, one month and two months). Anthropometric (weight, height, waist and hip circumference) and biochemical (glucose and cholesterol, triglycerides, HDL, LDL and VLDL) variables were evaluated, as well as blood pressure. Cardiometabolic risk predictors were evaluated, such as the triglyceride-glycemia index, the triglyceride/HDL-C index, the waist-height index (WHtR), the cardiometabolic index, the Lipid Accumulation Product and visceral adiposity index.
- Conditions
- Cardio Metabolic Risk
- Being tested
- Prasterone 50 milligram
- Keywords
- perimenopause and risk cardio metabolic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prasterone 50 milligramDrug
The participants were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (0, 4 and 8 weeks)
| Study group | Role | What they receive |
|---|---|---|
| Prasterone prescription | Experimental | The participantes were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (0, 4 and 8 weeks) Receives: Drug: Prasterone 50 milligram |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiometabolic risk
The primary objective is to assess the impact of oral DHEA therapy in perimenopausal women on cardiometabolic indicators.
Measured: Two months
Secondary outcomes (1)
Cardiometabolic risk
Assessing the effects of oral dehydroepiandrosterone (DHEA) therapy using the following indices:
- Triglyceride-Glucose Index (insulin resistance) Formula: ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)] / 2
- Triglyceride HDL-Cholesterol Index (HDL-C = high-density lipoprotein cholesterol) (Dyslipidemia; correlated with high-sensitivity C-reactive protein and metabolic syndrome) Formula: Triglycerides / HDL-cholesterol
- Waist-to-Height Ratio (Abdominal obesity) Formula: Waist circumference (cm) / Height (cm)
- Cardiometabolic Index (The relationship between total cholesterol and HDL cholesterol) Formula: Waist-to-height ratio (cm) × [Triglycerides / HDL-cholesterol ((mg/dL)]
- Lipid Accumulation Product Index (Oxidative) Formula: [Waist circumference (cm) - 58] × Triglycerides (mg/dL)
- Visceral Adiposity Index Formula: { Waist circumference (cm) / [ 36.58 + (1.89 × body mass index (kg/m) ] } × { (Triglycerides (mg/dL) / 0.81) × (1.52 / HDL-cholesterol (mg/dL)) }
Measured: 0, 4 and 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2026
- Study start10 Jan 2020
- Primary completion20 Dec 2020
- Study completion10 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Cardio Metabolic RiskStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This study was conducted in 25 women older than 42 years in the perimenopausal stage, with no history of breast cancer, hormonal replacement therapy, morbid obesity, cardiovascular disease, or diabetes mellitus. They were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (baseline, one month and two months). Anthropometric (weight, height, waist and hip circumference) and biochemical (glucose and cholesterol, triglycerides, HDL, LDL and VLDL) variables were evaluated, as well as blood pressure. Cardiometabolic risk predictors were evaluated, such as the triglyceride-glycemia index, the triglyceride/HDL-C index, the waist-height index (WHtR), the cardiometabolic index, the Lipid Accumulation Product and visceral adiposity index.
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad de Guanajuato
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lorena del Rocio Ibarra Reynoso, Universidad de Guanajuato
- Investigators
- Lorena Ibarra Reynoso, PhD, Principal investigator, Universidad de Guanajuato
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07609043
- Sponsor's protocol ID
- CIBIUG-P38-2016
- Status last verified
- May 2026
- First submitted
- 1 Apr 2023
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rabijewski M, Papierska L, Binkowska M, Maksym R, Jankowska K, Skrzypulec-Plinta W, Zgliczynski W. Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women - position statement of expert panel of Polish Menopause and Andropause Society. Ginekol Pol. 2020;91(9):554-562. doi: 10.5603/GP.2020.0091.
PubMed 33030737Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Hirschberg AL, Kiesel L, Lopes P, Pines A, van Trotsenburg M, Lambrinoudaki I, Rees M. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020 May;135:82-88. doi: 10.1016/j.maturitas.2020.03.007. Epub 2020 Mar 16.
PubMed 32209279Teixeira CJ, Veras K, de Oliveira Carvalho CR. Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period. J Mol Med (Berl). 2020 Jan;98(1):39-57. doi: 10.1007/s00109-019-01842-5. Epub 2019 Nov 12.
PubMed 31713639Vegunta S, Kling JM, Kapoor E. Androgen Therapy in Women. J Womens Health (Larchmt). 2020 Jan;29(1):57-64. doi: 10.1089/jwh.2018.7494. Epub 2019 Nov 5.
PubMed 31687883Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020 Jan;153:108507. doi: 10.1016/j.steroids.2019.108507. Epub 2019 Oct 3.
PubMed 31586606Teixeira CJ, Ribeiro LM, Veras K, da Cunha Araujo LC, Curi R, de Oliveira Carvalho CR. Dehydroepiandrosterone supplementation is not beneficial in the late postmenopausal period in diet-induced obese rats. Life Sci. 2018 Jun 1;202:110-116. doi: 10.1016/j.lfs.2018.03.052. Epub 2018 Mar 27.
PubMed 29601891Oh H, Wild RA, Manson JE, Bea JW, Shadyab AH, Pfeiffer RM, Saquib N, Underland L, Anderson GL, Xu X, Trabert B. Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2018-2029. doi: 10.1158/1055-9965.EPI-21-0604. Epub 2021 Aug 26.
PubMed 34446472Tang J, Chen LR, Chen KH. The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview. Pharmaceuticals (Basel). 2021 Dec 29;15(1):46. doi: 10.3390/ph15010046.
PubMed 35056103Martinez-Garcia G, Rodriguez-Ramos M, Santos-Medina M, Mata-Cuevas LA, Carrero-Vazquez AM, Chipi-Rodriguez Y. Triglyceride-glucose index impact on in-hospital mortality in acute myocardial infarction. Results from the RECUIMA multicenter registry. Gac Med Mex. 2022;158(2):83-89. doi: 10.24875/GMM.M22000646.
PubMed 35763827Lu Y, Liu S, Qiao Y, Li G, Wu Y, Ke C. Waist-to-height ratio, waist circumference, body mass index, waist divided by height0.5 and the risk of cardiometabolic multimorbidity: A national longitudinal cohort study. Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2644-2651. doi: 10.1016/j.numecd.2021.05.026. Epub 2021 Jun 4.
PubMed 34226121Liu X, Wu Q, Yan G, Duan J, Chen Z, Yang P, Bragazzi NL, Lu Y, Yuan H. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype. J Endocrinol Invest. 2021 Jun;44(6):1253-1261. doi: 10.1007/s40618-020-01417-z. Epub 2020 Sep 9.
PubMed 32909175Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Association of endogenous DHEA/DHEAS with coronary heart disease: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):984-994. doi: 10.1111/1440-1681.13146. Epub 2019 Aug 29.
PubMed 31347187Wakabayashi I, Daimon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015 Jan 1;438:274-8. doi: 10.1016/j.cca.2014.08.042. Epub 2014 Sep 6.
PubMed 25199852Baez-Duarte BG, Zamora-Ginez I, Rodriguez-Ramirez SO, Pesqueda-Cendejas LK, Garcia-Aragon KH. TG/HDL index to identify subjects with metabolic syndrome in the Mexican population. Gac Med Mex. 2022;158(5):259-264. doi: 10.24875/GMM.M22000693.
PubMed 36572023Farinola MG, Sganga M. [Cut-off points of anthropometric markers for hypertension and hyperglycemia in Argentine adults: a cross-sectional study from the 4th ENFR]. Rev Fac Cien Med Univ Nac Cordoba. 2022 Sep 16;79(3):260-266. doi: 10.31053/1853.0605.v79.n3.37313. Spanish.
PubMed 36149065
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Prasterone on Cardiometabolic Indicators in Perimenopausal Women.
- ClinicalTrials.gov ID
- NCT07609043
- Acronym / sponsor ID
- CIBIUG-P38-2016
- Conditions
- Cardio Metabolic Risk
- Keywords
- perimenopause and risk cardio metabolic
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- Universidad de GuanajuatoUniversity, hospital or other
- Study start
- 10 Jan 2020 (actual)
- Primary completion
- 20 Dec 2020 (actual)
- Study completion
- 10 Jan 2021 (actual)
- First posted
- 27 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Perimenopause is the natural transition period towards menopause, in which the ovarian reserve begins to decrease, and the woman loses her fertility. It usually starts around the age of 40 and has a variable duration. It has been identified that the decrease in estrogen levels leads to the development of metabolic and cardiovascular complications, such as metabolic syndrome. Dehydroepiandrosterone (DHEA) is a hormone that converts to testosterone and estrogen and is mainly associated with age-related changes in cardiovascular tissues and metabolism, among others. This hormone declines with age, contributing to the development of age-related disorders, such as cardiovascular disease. In theory, DHEA has beneficial effects in regulating glucose and lipid metabolism and in ameliorating obesity. It is hypothesized that DHEAS and cardiovascular disease may share causal pathways, for example, nitric oxide synthesis and endothelial cell damage. In addition, it has been observed that the administration of DHEA significantly reduces the level of triglycerides and improves insulin sensitivity. There are few studies focused on the perimenopause stage and none of them focused on the prevention of cardiometabolic risk. Therefore, evaluating the impact of prasterone on cardiometabolic indicators in premenopausal women is essential.
Detailed description
Perimenopause is the natural transition period towards menopause, in which the ovarian reserve begins to decrease, and the woman loses her fertility. It usually starts around the age of 40 and has a variable duration. It has been identified that the decrease in estrogen levels leads to the development of metabolic and cardiovascular complications, such as metabolic syndrome. Dehydroepiandrosterone (DHEA) is a hormone that converts to testosterone and estrogen and is primarily associated with age-related changes in cardiovascular tissues, female fertility, and metabolism, among others. This hormone gradually declines with age, contributing to the development of age-related disorders, such as cardiovascular disease. In theory, DHEA has beneficial effects in regulating glucose and lipid metabolism and in ameliorating obesity. Previous studies have shown that DHEA is inversely associated with cholesterol levels, obesity, and diabetes, playing an important preventive role in cardiovascular disease. It is hypothesized that DHEAS and cardiovascular disease may share causal pathways, for example, nitric oxide synthesis and endothelial cell damage. Some studies in premenopausal women found inverse correlations between serum DHEA concentrations and body weight. Besides. It has been observed that the administration of DHEA significantly reduces the level of triglycerides and improves insulin sensitivity. A meta-analysis showed that DHEAS was lower in patients with coronary disease, therefore, it is suggested that low levels of DHEAS may be a risk factor for coronary disease, affecting quality of life, and increasing the risks that predispose to metabolic diseases. Most of the studies where DHEA is administered are focused on the menopause stage, there being few studies focused on the perimenopause stage and none of them on the prevention of Cardiometabolic risk. For this reason, it is important to carry out studies to find out the effects that prasterone has on cardiometabolic indicators and that can contribute to the understanding of these processes before menopause appears. This study was conducted in 25 women older than 42 years in the perimenopausal stage, with no history of breast cancer, hormonal replacement therapy , morbid obesity, cardiovascular disease, or diabetes mellitus. They were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (baseline, one month and two months). Anthropometric (weight, height, waist and hip circumference) and biochemical (glucose and cholesterol, triglycerides, HDL, LDL and VLDL) variables were evaluated, as well as blood pressure. Cardiometabolic risk predictors were evaluated, such as the triglyceride-glycemia index, the triglyceride/HDL-C index, the waist-height index (WHtR), the cardiometabolic index, the Lipid Accumulation Product and visceral adiposity index.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This study was conducted in 25 women older than 42 years in the perimenopausal stage, with no history of breast cancer, hormonal replacement therapy, morbid obesity, cardiovascular disease, or diabetes mellitus. They were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (baseline, one month and two months). Anthropometric (weight, height, waist and hip circumference) and biochemical (glucose and cholesterol, triglycerides, HDL, LDL and VLDL) variables were evaluated, as well as blood pressure. Cardiometabolic risk predictors were evaluated, such as the triglyceride-glycemia index, the triglyceride/HDL-C index, the waist-height index (WHtR), the cardiometabolic index, the Lipid Accumulation Product and visceral adiposity index.
| Arm | Type | Receives |
|---|---|---|
| Prasterone prescription | Experimental | Drug: Prasterone 50 milligramThe participantes were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (0, 4 and 8 weeks) |
Who may qualify
- Ages
- 42 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- with no history of breast cancer, HRT, morbid obesity, cardiovascular disease, or DM.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prasterone 50 milligramThe participants were prescribed 50mg/day of prasterone for a period of 2 months, making 3 measurements (0, 4 and 8 weeks) | Drug | Prasterone prescription |
Primary outcome
Cardiometabolic risk
Time frame: Two months
The primary objective is to assess the impact of oral DHEA therapy in perimenopausal women on cardiometabolic indicators.
1 secondary outcome
Cardiometabolic risk
Time frame: 0, 4 and 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Background: PubMed 33030737Rabijewski M, Papierska L, Binkowska M, Maksym R, Jankowska K, Skrzypulec-Plinta W, Zgliczynski W. Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women - position statement of expert panel of Polish Menopause and Andropause Society. Ginekol Pol. 2020;91(9):554-562. doi: 10.5603/GP.2020.0091.
- Background: PubMed 32209279Anagnostis P, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Hirschberg AL, Kiesel L, Lopes P, Pines A, van Trotsenburg M, Lambrinoudaki I, Rees M. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas. 2020 May;135:82-88. doi: 10.1016/j.maturitas.2020.03.007. Epub 2020 Mar 16.
- Background: PubMed 31713639Teixeira CJ, Veras K, de Oliveira Carvalho CR. Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period. J Mol Med (Berl). 2020 Jan;98(1):39-57. doi: 10.1007/s00109-019-01842-5. Epub 2019 Nov 12.
- Background: PubMed 31687883Vegunta S, Kling JM, Kapoor E. Androgen Therapy in Women. J Womens Health (Larchmt). 2020 Jan;29(1):57-64. doi: 10.1089/jwh.2018.7494. Epub 2019 Nov 5.
- Background: PubMed 31586606Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020 Jan;153:108507. doi: 10.1016/j.steroids.2019.108507. Epub 2019 Oct 3.
- Background: PubMed 29601891Teixeira CJ, Ribeiro LM, Veras K, da Cunha Araujo LC, Curi R, de Oliveira Carvalho CR. Dehydroepiandrosterone supplementation is not beneficial in the late postmenopausal period in diet-induced obese rats. Life Sci. 2018 Jun 1;202:110-116. doi: 10.1016/j.lfs.2018.03.052. Epub 2018 Mar 27.
- Background: PubMed 34446472Oh H, Wild RA, Manson JE, Bea JW, Shadyab AH, Pfeiffer RM, Saquib N, Underland L, Anderson GL, Xu X, Trabert B. Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2018-2029. doi: 10.1158/1055-9965.EPI-21-0604. Epub 2021 Aug 26.
- Background: PubMed 35056103Tang J, Chen LR, Chen KH. The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview. Pharmaceuticals (Basel). 2021 Dec 29;15(1):46. doi: 10.3390/ph15010046.
- Background: PubMed 35763827Martinez-Garcia G, Rodriguez-Ramos M, Santos-Medina M, Mata-Cuevas LA, Carrero-Vazquez AM, Chipi-Rodriguez Y. Triglyceride-glucose index impact on in-hospital mortality in acute myocardial infarction. Results from the RECUIMA multicenter registry. Gac Med Mex. 2022;158(2):83-89. doi: 10.24875/GMM.M22000646.
- Background: PubMed 34226121Lu Y, Liu S, Qiao Y, Li G, Wu Y, Ke C. Waist-to-height ratio, waist circumference, body mass index, waist divided by height0.5 and the risk of cardiometabolic multimorbidity: A national longitudinal cohort study. Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2644-2651. doi: 10.1016/j.numecd.2021.05.026. Epub 2021 Jun 4.
- Background: PubMed 32909175Liu X, Wu Q, Yan G, Duan J, Chen Z, Yang P, Bragazzi NL, Lu Y, Yuan H. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype. J Endocrinol Invest. 2021 Jun;44(6):1253-1261. doi: 10.1007/s40618-020-01417-z. Epub 2020 Sep 9.
- Background: PubMed 31347187Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Association of endogenous DHEA/DHEAS with coronary heart disease: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2019 Nov;46(11):984-994. doi: 10.1111/1440-1681.13146. Epub 2019 Aug 29.
- Individual participant dataSharing planned: No
Related trials for Cardio Metabolic Risk
Recruiting
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
Type 2 Diabetes, Coronary Heart Disease
Active, not recruitingObservational study
Metabolic Status and Risk of Chronic Kidney Disease in French Overseas Populations With Morbid Obesity (OBECAMcohort).
Morbid Obesity, Chronic Kidney Disease (Stage 3-4)
Not yet recruitingObservational study
Holistic CRM Care vs Standard of Care in a Primary Care Setting
Cardio Vascular Disease, Diabetes (DM)
Recruiting
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
Diabetic Kidney Disease (DKD), Type 2 Diabetes Mellitus (T2DM)
Recruiting
Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lorena Ibarra Reynoso, PhD principal investigator
Universidad de Guanajuato
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Prasterone 50 milligram in people with Cardio Metabolic Risk, run by Universidad de Guanajuato at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiometabolic risk (time frame: Two months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07609043, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.